Pendulum Therapeutics Raises $54 million Gut health biotech company Pendulum Therapeutics recently announced a $54 million investment led by Meritech Capital with participation from existing investors including Sequoia Capital, True Ventures and Khosla Ventures.
The Series C round nearly doubled the entirety of Pendulum’s previous raises, bringing the total venture capital raised to $111 million.
As lead investor, Meritech General Partner Craig Sherman will take a seat on the Pendulum Board of Directors alongside Roelof Botha, a partner at Sequoia, and Adam D’Augelli, a partner at True Ventures.
“We think Pendulum is a next generation pharma company doing next generation gene sequencing,” said Sherman.
Modular Medical Establishes a Distinguished Multi-Disciplinary Advisory Board
tennesseedaily.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from tennesseedaily.com Daily Mail and Mail on Sunday newspapers.
Computational Science Disruption In Biopharma Discovery
pharmaceuticalonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmaceuticalonline.com Daily Mail and Mail on Sunday newspapers.
To embed, copy and paste the code into your website or blog:
Welcome to our monthly roundup of regulatory and litigation highlights impacting the dietary supplement and personal care products industries. Sit back, relax, and enjoy the read. February was a short month, with a lot going on.
NAD
Health claim substantiation was front and center before NAD in a monitoring case involving Pendulum Therapeutics and a “medical probiotic” product featuring claims such as “The only medical probiotic clinically shown to lower A1C & blood glucose spikes for the dietary management of T2D ” ( Consult your physician as part of your total diabetes management plan. Results may vary from person to person.”)